Long Term Investment, Biotech & High Yield Dividend Stocks

[califax]

ASCO Stocks Presenting New Clinical Data - SNSS

By Adam Feuerstein 05/21/10 - 06:00 AM EDT
http://www.thestreet.com/story/10762345/12/13-asco-stocks-presenting-new-clinical-data.html



Drug: Voreloxin
Abstract No. 5002
Indication: ovarian cancer
Clinical Trial: Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer.
Presentation Time: Monday, June 7. Oral session.
Notes: Final response rate across three different dosages of Voreloxin was 11% with a median progression-free survival of 84 days.

Sunesis will also be presenting final phase II data from a study of voreloxin in patients with acute myeloid leukemia.

#####################################################################################################

Posted by: read_this_n0w
http://investorshub.advfn.com/boards/board.aspx?board_id=4349

Voreloxin abstract
http://abstract.asco.org/AbstView_74_49315.html

Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer.
http://abstract.asco.org/AbstView_74_48872.html

Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia.
http://abstract.asco.org/AbstView_74_49274.html

Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules
http://abstract.asco.org/AbstView_74_49315.html